Pradaxa antidote reverses anticoagulation-Boehringer

Presented for the first time at the American Heart Association�s (AHA) Scientific Sessions, results from the first clinical study in healthy volunteers demonstrate the potential of an antibody fragment (Fab) as a specific antidote for immediate, complete and sustained reversal of Pradaxa ( dabigatran-induced anticoagulation) from Boehringer. The antibody fragment has not yet been approved for clinical use and is still undergoing investigation to further establish its efficacy and safety profile.

The trial reported - All administered doses of the antibody fragment antidote were well tolerated -A 5-minute infusion of the antidote following Pradaxa pre-treatment was able to achieve immediate, complete and sustained reversal of the anticoagulant effect of dabigatran - For the 2 g and the 4 g doses, the reversal effect was maintained for more than 12 hours after the end of infusion.